Adaptimmune Therapeutics PLC SEC filings ADAPY

Adaptimmune Therapeutics PLC has 808 filings in SEC EDGAR's recent list, going back to Oct 2, 2014. Its latest annual report, Form ARS, was filed on Apr 25, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2025, covering the quarter ended Jun 30, 2025. The most recent current report (Form 8-K) was filed on Oct 20, 2025 (listing notice, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 25, 2025 Dec 31, 2024
10-K Annual report Mar 24, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 22, 2024 Dec 31, 2023
10-K Annual report Mar 6, 2024 Dec 31, 2023
10-K Annual report Mar 6, 2023 Dec 31, 2022
10-K Annual report Mar 14, 2022 Dec 31, 2021
10-K Annual report Feb 25, 2021 Dec 31, 2020
10-K Annual report Feb 27, 2020 Dec 31, 2019
10-K Annual report Feb 27, 2019 Dec 31, 2018
10-K Annual report Mar 15, 2018 Dec 31, 2017
10-K Annual report Mar 13, 2017 Dec 31, 2016
20-F Annual report (foreign issuer) Mar 17, 2016 Dec 31, 2015
20-F Annual report (foreign issuer) Oct 13, 2015 Jun 30, 2015

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ADAPY (OTC)
Fiscal year ends
December 31
Incorporated in
United Kingdom
Headquarters
Abingdon, Oxfordshire
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1621227
Former names
Adaptimmune Ltd (until Mar 17, 2015)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.